Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Dividend history for Celltrion, Inc. (068270.KS)
Celltrion, Inc. made a total of 8 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $1.37
Dividend payments for Celltrion, Inc. (068270.KS) from 2006 to 2023
Annual dividend payments
| Date | Dividend | Adj Dividend |
|---|---|---|
| December 27, 23 | $0.36 | $0.36 |
| December 28, 22 | $0.27 | $0.27 |
| December 29, 21 | $0.54 | $0.52 |
| December 27, 12 | $0.01 | $0.01 |
| December 28, 11 | $0.07 | $0.06 |
| December 29, 10 | $0.05 | $0.04 |
| December 27, 07 | $0.04 | $0.03 |
| December 27, 06 | $0.04 | $0.03 |